NOVAREMED AG
Novaremed AG is a clinical-stage Swiss biopharmaceutical company.
NOVAREMED AG
Social Links:
Industry:
Biotechnology
Founded:
2017-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.novaremed.com
Total Employee:
1+
Status:
Active
Total Funding:
52.62 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible WordPress Font Awesome Euro Contact Form 7 WPBakery WordPress 5.2
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-09-07 | Metys Pharmaceuticals | Metys Pharmaceuticals acquired by Novaremed AG | N/A |
Investors List
The Global Emerging Markets Group
The Global Emerging Markets Group investment in Private Equity Round - Novaremed AG
Official Site Inspections
http://www.novaremed.com Semrush global rank: 5.29 M Semrush visits lastest month: 1.56 K
- Host name: ec2-18-102-82-159.eu-south-1.compute.amazonaws.com
- IP address: 18.102.82.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Novaremed AG"
Home | Novaremed
Jan 31, 2023 · Novaremed aims to address high unmet patient and societal needs for better relief from pain and peripheral neuropathy associated with diabetes and cancer chemotherapy by …See details»
Novaremed AG – Swiss Biotech
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is innovating chronic pain management through the development of effective and safe treatment options as an …See details»
Novaremed AG - Crunchbase Company Profile & Funding
Novaremed AG is a clinical-stage Swiss biopharmaceutical company. An investigational non-opioid small molecule for the treatment of painful diabetic peripheral neuropathy (PDPN), …See details»
Novaremed AG - LinkedIn
Focused on Pain | Novaremed AG is a clinical-stage Swiss biopharmaceutical company, HQ in Basel, Switzerland, with a subsidiary in Israel. Novaremed is developing an orally active,...See details»
Novaremed Company Profile 2024: Valuation, Funding & Investors …
Developer of pharmaceutical drugs using small bio-molecules designed for the treatment of neuropathic pain.See details»
News September 7, 2021 | Novaremed
Basel, Switzerland, September 7, 2021 – Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG …See details»
News June 23, 2022 | Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet …See details»
Organization | Novaremed Ltd.
Novaremed Ltd. Report issue For profit Phase 2 Founded: Israel (2008)See details»
Novaremed acquires Metys Pharmaceuticals and strengthens …
Sep 7, 2021 · Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its …See details»
Novaremed Company Profile - Office Locations, Competitors
Novaremed is clinical-stage biopharmaceutical company. It develops an orally active non-opioid small molecule to treat diabetic neuropathic pain.See details»
News - Novaremed
Dec 22, 2020 · Novaremed receives Fast Track Designation from the FDA for NRD135S.E1 for treatment of Painful Diabetic Peripheral Neuropathy. Novaremed Announces Closing of a New …See details»
Novaremed’s lead compound in Phase 2 trial for treatment of …
After a thorough review by pain experts, Novaremed has received NIH confirmation for funding and execution of a Phase 2b study with NRD.E1 in patients with PDPN.See details»
Novaremed Expands its Pipeline of Non-opioid Treatment …
Sep 7, 2021 · Novaremed AG, a privately held clinical-stage biopharmaceutical company, is innovating chronic pain management through the development of effective and safe treatment …See details»
Novaremed Announces Publication of Phase 1 and Phase 2a
Jun 23, 2022 · Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the …See details»
News July 21, 2022 | Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet …See details»
News January 31, 2023 | Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet …See details»
Novaremed Secures US $50 Million Capital Commitment from …
Jan 28, 2021 · BASEL, Switzerland-- ( BUSINESS WIRE )--Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an …See details»
Novaremed Receives Fast Track Designation from the FDA for …
Dec 18, 2020 · Novaremed Ltd is developing NRD135S.E1, an orally active non-opioid small molecule with a novel mechanism of action against PDPN. In a Phase 2a Proof of Concept …See details»
News January 28, 2021 | Novaremed
BASEL, Switzerland– ( BUSINESS WIRE )–Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with GEM …See details»
Novaremed agreement with NeuroFront for non-opioid …
Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremed’s …See details»